Drugs / DWC202518
last change Jun 2026 re-read 2 minutes ago

DWC202518

Developed for
type 2 diabetes mellitus
Investigated by
Daewoong Pharmaceutical Co. LTD.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07619833 Jun 2026 → Nov 2027 expected type 2 diabetes mellitus Daewoong Pharmaceutical Co. LTD. Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DWC202518 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07619833
Route Oral Orally” NCT07619833